119 results about "Vitiligo" patented technology

The invention discloses an application of betulinic acid 28-O-beta-D-glucoside (BA-6 for short) in preparation of a medicine for preventing and treating skin inflammation. The problems that an existing medicine for treating dermatitis is limited in curative effect, slow in effect taking, multiple in side effect, high in long-term use risk, large in individual difference, high in treatment cost, likely to cause immunoreaction and the like are solved. The invention discloses application of BA-6 in prevention and treatment of atopic dermatitis, contact dermatitis, eczema, rash, psoriasis, lupus erythematosus, papule squamous skin disease, pityriasis rosea, seborrheic dermatitis, pemphigus, celestial abscess, acne, tinea corporis, impetigo, SAPHO syndrome, hidradenitis suppurativa, dermatitis caused by drugs, lichen planus, pityriasis rubra pilaris, vitiligo, prurigo nodularis, dermatitis caused by drugs, and the like for the first time. The traditional Chinese medicine composition can be used for treating skin diseases, systemic sclerosis, hidradenitis suppurativa, granulomatous skin diseases, vitiligo, dermatomyositis, chronic skin itch and alopecia areata, and has the technical progress of obviously improving skin erythema, papule, edema, scale, moss and ulceration symptoms.

The application provides a tyrosinase-based transdermal delivery system for treating vitiligo, which is a core-shell structure, the core is tyrosinase, and the shell is a polymer shell layer. The application coats a polymer protective layer on the surface of the tyrosinase through in-situ polymerization reaction on the double bond of the tyrosinase, can effectively protect the activity of the tyrosinase and promote the transdermal delivery of the tyrosinase, and can control the targeted delivery of the tyrosinase nanogel to melanocytes in the deep part of the skin and hair follicle by adjusting the polymerization conditions of the polymer shell, so as to promote the in-situ synthesis of melanin. The transdermal delivery system of the application can also load active small molecules with anti-inflammatory function in the center of the tyrosinase, and the small molecules are released after being targeted and delivered to the inflammation area of vitiligo along with the tyrosinase nanogel, so as to relieve inflammation and protect melanocytes from damage.

The invention discloses a method for determining chemical components in a medicine for treating vitiligo and a method for establishing a fingerprint spectrum. Comprising the following steps: S1, preparing a to-be-detected solution and a reference substance solution: grinding Bailing tablets, dissolving the Bailing tablets in a solvent, and extracting to prepare the to-be-detected solution; dissolving a paeoniflorin reference substance in a solvent to prepare a reference substance solution; wherein the extraction solvent is a methanol-water mixed solution; s2, respectively obtaining chromatograms of the to-be-detected solution and the reference substance solution under the same detection conditions by adopting ultra-high performance liquid chromatography, and carrying out qualitative analysis and / or quantitative analysis on chemical components in the chromatograms of the to-be-detected solution; wherein the detection conditions are as follows: the wavelength of a detector is 201 + / -2nm; the elution conditions are as follows: acetonitrile is used as a phase A, water is used as a phase B, and elution is performed through a gradient elution procedure. According to the method, the chemical components in the medicine for treating the leucoderma can be accurately determined, so that the establishment of the fingerprint spectrum database of the medicine for treating the leucoderma can be better realized.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

The present disclosure relates to topical formulations and methods of treating skin diseases using topical formulations comprising a JAK 1 / 2 inhibitor, which is ruxolitinib, or a pharmaceutically acceptable salt thereof, and an organic amine pH adjusting agent. The skin diseases for treatment include, but are not limited to, psoriasis, atopic dermatitis, alopecia, vitiligo, Reiter's syndrome, pityriasis rubra pilaris, epidermolysis bullosa simplex, palmoplantar keratoderma, pachyonychia congenita, steatocystoma multiplex, cutaneous lichen planus, cutaneous T-cell lymphoma, hidradenitis suppurativa, contact dermatitis, ichthyosis, and a disorder of keratinization. The organic amine pH adjusting agent is a tertiary amine or an alkanol amine.

The invention discloses a preparation method of drug-loaded membrane protein bionic vesicles based on a microfluidic technology and application of the drug-loaded membrane protein bionic vesicles to targeted melanocyte delivery drugs, and belongs to the technical field of pharmaceutical preparations. The method is easy and convenient to operate, assembly of the phospholipid bilayer and insertion of the membrane protein are accurately controlled through the laminar focusing technology, and the stable and efficient drug-loaded membrane protein bionic vesicle is formed. The drug-loaded membrane protein bionic vesicles can effectively target melanocytes, promote the uptake of the vesicles, significantly improve the accumulation of drugs in the melanocytes, and enhance the treatment effect on melanocyte related diseases (such as hyperpigmentation, melanoma, vitiligo and the like). Meanwhile, the drug-loaded bionic vesicles constructed by the invention have relatively low keratinocyte uptake rate, drug uptake of non-targeted tissues is effectively reduced, and side effects of drugs are reduced, so that the drug-loaded membrane protein bionic vesicle system constructed by the invention has great prospects in the aspect of treating melanocyte related diseases.

The utility model provides a vitiligo novel target ultraviolet light therapeutic instrument, relates to skin treatment equipment technical field, including base, console, adjusting tube and phototherapy head, the console is installed on the base, the adjusting tube connects the console and the phototherapy head, the phototherapy head is provided with ultraviolet light source inside, and the ultraviolet light source is connected with the base. The front end of the phototherapy head is provided with an adjustable light shield, so that the problems that the irradiation range of the phototherapy head cannot be adjusted, a vitiligo disease area is not targeted, and surrounding normal skin can be irradiated in the use process of an existing ultraviolet light therapeutic apparatus can be solved; and the problems that the irradiation position and angle are not easy to fix when a traditional handheld phototherapy head is used for irradiation, and the phototherapy head is directly contacted with the skin due to mistaken touch are solved.

The invention relates to a method for rapidly preparing vernonia anthelmintica dealicin from vernonia anthelmintica dealicin, which comprises the following steps: carrying out ultrasonic extraction by using ethanol, enriching by using macroporous resin to obtain a vernonia anthelmintica dealicin extract, and carrying out extraction and pilot plant test preparative liquid chromatography separation to obtain a high-purity vernonia anthelmintica dealicin compound. The results of subsequent researches show that the vernonia anthelmintica dealicin can significantly inhibit the secretion of the chemotactic factor, and the inhibition rate of 1mol / L of vernonia anthelmintica dealicin on the release level of the chemotactic factor CXCL10 reaches 75.83%. The vernonia anthelmintica macrobrachin reduces the recruitment of self-reactive T cells to the skin by blocking a CXCL10-mediated inflammation signal channel, so that melanocytes are protected, and pigment regeneration is promoted. Therefore, the vernonia anthelmintica macrobrachin inhibits the secretion of the chemotactic factor CXCL10 in a targeted manner, can be used as a potential effective monomeric compound in the development of vitiligo medicines for research, and is expected to become a new strategy for treating vitiligo.

The invention discloses observation of the curative effect of AKBA gel combined with narrow-spectrum UVB irradiation in treatment of leucoderma. The invention creatively discovers that the combined use of AKBA and phototherapy has a remarkable and better treatment effect on leucoderma for the first time, provides an effective drug combination strategy for treatment of leucoderma, and has a good clinical application prospect and important conversion significance in the technical field of research and development of leucoderma treatment drugs.

The composition is prepared from the following components in parts by weight: 150-250 parts of radix angelicae, 200-350 parts of peach kernels, 20-60 parts of honeysuckle flowers, 10-30 parts of red roses with double petals, 20-40 parts of dried ginger and 10-30 parts of Chinese dates, meridian tropism, property, flavor and function analysis is performed on a meridian prescription, medicinal and edible homology replacement is performed, and under the control of clear quality indexes, the composition is obtained through extraction, and the composition is used for treating leucoderma. Activity tests prove that the traditional Chinese medicine composition has the effect of assisting in improving vitiligo. The invention further discloses a preparation process and an analysis method of the composition for assisting in improving vitiligo.

The invention discloses application of an ATP (adenosine triphosphate) citrate lyase (ACLY) inhibitor in preparation of a medicine for treating leucoderma, and belongs to the technical field of preparation of medicines for treating leucoderma. Through targeted inhibition of ACLY activity or specific knockout of ACLY in CD8 + T cells, abnormal activation of ACLY and secretion of killing effector molecules (Granzyme B, IFN-gamma, Perforin and the like) are inhibited, and infiltration of the CD8 + T cells to skin lesion parts is reduced, so that melanocytes are protected from immune injury, and the progress of vitiligo is blocked. The application is based on the abnormally high expression of ACLY in CD8 + T cells of vitiligo patients and the close association with disease activity, and a brand new targeted treatment thought and a medicine research and development direction are provided for vitiligo.

1. Name of the product in this design: Ultraviolet Phototherapy Device (308 nm). 2. Intended use of this design: Treatment of psoriasis and vitiligo. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

The invention discloses application of rifudine in preparation of a preparation for promoting cell melanin synthesis, and belongs to the technical field of special drugs. The invention provides a new application of rifudine, which can promote synthesis and secretion of melanin and expression of TYR, TRP-1 and TRP-2, provides a new functional component for enhancing synthesis of melanin in vivo and preparing products for treating vitiligo and the like, and has a wide application prospect in the fields of pharmaceutical preparations, cosmetics, care products, beauty products and the like.

The invention discloses a traditional Chinese medicine for treating leucoderma and a preparation method thereof, and relates to the technical field of traditional Chinese medicines. Comprising medicine for oral administration, astragalus membranaceus, codonopsis pilosula, bighead atractylodes rhizome, rhizoma smilacis glabrae, Chinese yam, fructus psoraleae, angelica sinensis, buffalo horn shreds, dogwood, salvia miltiorrhiza, red paeony root, safflower carthamus, ligusticum wallichii, peach kernel, polygonum multiflorum, eclipta alba, white mulberry root-bark, divaricate saposhnikovia root, radix bupleuri, scutellaria baicalensis, curcuma aromatica, fingered citron, rhizoma cyperi, felwort, parched white peony root, tribulus terrestris, gardenia, radix angelicae and rhizoma typhonii. The external immersion liquid comprises fructus psoraleae, radix angelicae, cortex dictamni, radix polygoni multiflori, borax, rhizoma typhonii, semen cuscutae, flos carthami and white spirit. Through oral administration for regulating qi and blood, tonifying liver and kidney, dredging meridians and collaterals and consolidating root, external application for dredging local parts and promoting pigment, internal and external synergism and simultaneous treatment of both symptoms and root causes, the traditional Chinese medicine is especially suitable for middle-aged and elderly patients with qi and blood deficiency, deficiency of liver and kidney and qi stagnation and blood stasis type leucoderma.

This specification discloses FABP inhibitor compounds and their use in pharmaceutical compositions for treating diseases that highly express any of these FABPs, including cancers, particularly triple-negative breast cancer (TNBC), and other pro-inflammatory diseases, including cardiovascular diseases, obesity or obesity-related disorders, diabetes, dyslipidemia, impaired glucose tolerance or impaired fasting blood glucose, vitiligo, psoriasis, autoimmune disorders, pain, and dementia. This specification also discloses methods for preparing the disclosed compounds.

The application discloses a chitosan-glycine-copper chelate and a preparation method and application thereof in treating leukoplakia and vitiligo. In the preparation, chitosan is first placed in an acid aqueous phase system, and is fully dissolved and forms a uniform transparent or translucent solution under stirring; then glycine is added, and the chitosan and the glycine are fully mixed under stirring to build an organic ligand environment containing multiple coordination groups; subsequently, a copper source is introduced to perform a chemical reaction, and finally the chitosan-glycine-copper chelate is obtained. The chitosan-glycine-copper chelate shows a strong promoting activity completely different from all other substances (including simple mixtures of components thereof), the chelate can continuously and significantly activate tyrosinase activity, and promote the formation of melanin, so that the purpose of treating leukoplakia and vitiligo is achieved.

The application discloses a compound morinda officinalis color-increasing liniment for treating vitiligo and a preparation method thereof, and particularly relates to the technical field of traditional Chinese medicine preparations, wherein the liniment is prepared from morinda officinalis, spilanthes acmella, giant knotweed, caesalpinia sappan, psoralea corylifolia, radix angelicae dahuricae and rhizoma smilacis glabrae as raw medicinal materials. The preparation method comprises the following steps: dynamic reflux extraction, percolation extraction, macroporous adsorption resin purification and preparation molding. Through the classification extraction and purification process, the photosensitive active ingredients are retained, and the photo-toxic impurities are effectively removed, so that the photo-toxicity is completely negative. The pharmacodynamic test shows that the liniment has a significant curative effect on vitiligo. The safety test shows that the liniment has no skin irritation and no allergenicity, and has excellent light safety. The quality research shows that the quality of the liniment is stable and controllable. The liniment has definite curative effect, high safety and stable quality, and has a good clinical application prospect.

The invention discloses an application of a substance for detecting a marker group. The application comprises one or more of the following applications: A1) an application in preparation of a product for predicting sensitivity of bicitinib combined with narrow-spectrum medium-wave ultraviolet rays in treatment of leucoderma, and A2) an application in preparation of a product for predicting sensitivity of bicitinib combined with narrow-spectrum medium-wave ultraviolet rays in treatment of leucoderma; a2) is applied to preparation of a product for screening sensitivity of bicitinib combined with narrow-spectrum medium-wave ultraviolet rays in treatment of leucoderma; a3) in preparation of a product for evaluating sensitivity of bicitinib combined with narrow-spectrum medium-wave ultraviolet rays in treatment of leucoderma; the marker group is composed of CCL5, FGL1, EZR and GAPDH (glyceraldehyde-phosphate dehydrogenase). The invention screens and verifies the plasma and urine biomarker group capable of predicting the sensitivity of treating leucoderma by combining baricitinib with narrow-spectrum medium-wave ultraviolet rays of a subject through ELISA (Enzyme-Linked Immunosorbent Assay), and the plasma and urine biomarker group provided by the invention has higher prediction accuracy, sensitivity and specificity; the individualized treatment of vitiligo can be improved, and good clinical application and popularization prospects are achieved.

The application discloses a mouse vitiligo induction model based on chronic stress factors, wherein different kinds of stress factors capable of triggering stress response of animals are applied to stimulate the mouse periodically within a certain time period, so as to prevent the mouse from producing habitual response to the stress source and to promote the mouse to become white and the tail epidermis to be flaky. The technical method is different from the existing vitiligo model method, is based on the mechanism of occurrence and development of vitiligo observed in the clinic, and promotes the mouse to truly develop the vitiligo phenomenon from the whole instead of simulating the disease evolution locally. Compared with the existing vitiligo promoting mechanism, the effect is more stable and the authenticity is higher. The technical method is based on the objective fact that the clinical vitiligo patients often combine anxiety and depression to design the stress factors, and considers that the stress factors and the occurrence and development of vitiligo may be inter-caused and viciously circulate, namely, the adverse life events as the stress factors cause the damage and dysfunction of the melanin synthesis system at the micro level and form the vitiligo change at the macro level.

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.

The present invention discloses the use of METTL3 enzyme inhibitors in the preparation of drugs for vitiligo and the drugs thereof, belonging to the technical field of vitiligo treatment. The present invention discloses the use of METTL3 enzyme inhibitors in the preparation of drugs for vitiligo, and the use of METTL3 enzyme inhibitors in the preparation of drugs for treating vitiligo, seeking a new treatment approach and drugs for treating vitiligo, thereby delaying the progression of vitiligo white patches and treating vitiligo.

The invention discloses a method for determining chemical components in a medicine for treating vitiligo, which relates to the technical field of medicine analysis, and is characterized in that ultra-high performance liquid chromatography-mass spectrometry is adopted to determine the content of chemical components in a Bailing tablet: psoralen, isopsoralen, astragaloside, quercetin, polysaccharide and amino acid. The determination method comprises the following steps: respectively injecting a reference solution and a test solution into a liquid chromatograph for determination to obtain a chromatogram, and calculating the content of paeoniflorin in a test sample by adopting an external standard method, chromatographic conditions of a chromatogram obtained by adopting a liquid chromatograph are as follows: octadecylsilane chemically bonded silica is taken as a filling agent. According to the method for determining the chemical components in the medicine for treating leucoderma, the established detection method is verified, and the result shows that the detection method is easy and convenient to operate, accurate in result, high in specificity and good in reproducibility.

1. Name of the product subject to this design: Laser Therapy Device (EXC-5001). 2. Purpose of this design: For use by medical institutions as an adjunct treatment for psoriasis and vitiligo. 3. The key design features of this product are the combination of shape and pattern. 4. The image or photograph that best illustrates the design's key points: a 3D model.

1. The name of the design product: excimer light therapy instrument (308nm). 2. The use of the design product: for the treatment of vitiligo. 3. The design points of the design product: in shape. 4. The picture or photo that best shows the design points: perspective view 1.

The utility model discloses a vitiligo treatment medicine smearing device which comprises a medicine bottle, an installation sleeve is arranged at the bottom end of the medicine bottle, a sealing mechanism is arranged in the installation sleeve, the sealing mechanism comprises a sealing sleeve, a sealing ring, a movable plate, a fixed sleeve and a limiting sleeve, the sealing sleeve is installed in the installation sleeve, the sealing ring is installed on the inner wall of the installation sleeve, and the movable plate is installed on the inner wall of the movable plate. The movable plate is attached to the top face of the sealing sleeve, the fixing sleeve is installed on the inner wall of the installation sleeve, the limiting sleeve is installed on the inner wall of the fixing sleeve, a medicine discharging mechanism is arranged on the movable plate, the sealing sleeve and a sealing ring are arranged in the installation sleeve to form a double-sealing structure of the sealing mechanism, and the movable plate and the sealing sleeve are tightly attached to be matched with multiple sets of sealing strips. Meanwhile, due to the combined design of a fixing sleeve and a limiting sleeve, the movement stability of the movable plate is guaranteed, the movable plate is prevented from shifting through the guiding effect of a limiting rod, the problem that in the prior art, sealing performance is insufficient is solved, and liquid medicine leakage and pollution are effectively avoided.

The present disclosure provides methods and compositions for treating a disease or condition involving inflammation in the skin, e.g., atopic dermatitis, eczema other than atopic dermatitis, hidradenitis suppurativa, vitiligo, alopecia areata, scleroderma (including systemic sclerosis), dermatomyositis, epidermolysis bullosa, mastocytosis, keloids, acne, rosacea, or bullous pemphigoid, with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody (Afimkibart).

The application provides a composition containing salicin, a product and application thereof, and relates to the technical field of cosmetics. Specifically, the application provides application of salicin in promoting intracellular melanin synthesis, and it is first proved that salicin can promote intracellular melanin synthesis by promoting tyrosinase activity, thereby providing a new functional ingredient for enhancing intracellular melanin synthesis, and preparing a product for improving and treating white hair and vitiligo.

A phototherapy system for treating a user can include an applicator, a controller, and a communication cable configured to couple the applicator and the controller. The applicator can include a light source, a thermal sensor, and a fan. The controller can be in communication with the applicator. The controller can be configured to receive a predetermined treatment regimen to be applied to the user via the applicator. A method for treating skin presenting psoriasis includes providing a phototherapy system. The user can select a skin type on the controller. The use can place the applicator adjacent to the skin presenting psoriasis, eczema, or vitiligo. The user can receive a light therapy treatment from the applicator, whereby the psoriasis, eczema, or vitiligo has been treated.

The invention relates to the technical field of skin detection equipment, and discloses an intelligent vitiligo detection device which comprises an intelligent detection and treatment equipment body, image acquisition equipment arranged on the intelligent detection and treatment equipment body and a hand placing and folding mechanism. The image acquisition equipment is fixed through a multi-angle adjusting frame, the angle can be flexibly adjusted to be attached to the skin, and uniform irradiation of ultraviolet light is guaranteed. The hand placing and folding mechanism comprises a lower folding plate which can be unfolded, through linkage of a telescopic rod and a spring, the device can adapt to hands of different sizes, and the universality of detection is improved. And the mechanism can also realize quick folding and storage towards the bottom of the equipment integrally through the matching of the positioning rod and the spring, and is compact in structure and convenient to store. The device further comprises an image processing system which can automatically segment a white spot area in the image, accurately calculate the area and the relative gray value of the white spot area and generate a quantitative analysis report. Through combination of structural innovation and intelligent analysis, accurate, objective and convenient detection of vitiligo conditions is realized.

The invention provides new application of an ATOX1 gene and ATOX1 protein, and belongs to the technical field of treatment of vitiligo diseases. The ATOX1 gene serving as a key gene of copper metabolism is disclosed for the first time, and melanin synthesis is promoted by activating the melanocyte copper metabolism process, so that the effect of resisting leucoderma is achieved. The ATOX1 gene and / or the ATOX1 protein can be used as a key biomarker in the vitiligo morbidity process, and a new target and a new molecular basis are provided for vitiligo research.